Valbiotis Teams up with Nestlé to Reduce Type 2 Diabetes Risk

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis complete phase II/III testing of its dietary supplement. The company hopes that this will then provide enough evidence for the US and EU to validate its claim that the supplement can reduce the risk of prediabetes progressing into full-blown type 2 diabetes.